Catheter Ablation -> Atrial Fibrillation & Atrial Flutter: -> Clinical Trials / Outcomes D-PO03 - Poster Session III (ID 48) Poster

D-PO03-179 - First Assessment Of Outcomes Catheter Ablation For Atrial Arrhythmias In Arrhyhtmogenic Cardiomyopathy (ID 1142)


Background: Arrhythmogenic cardiomyopathy (AC) is characterized by fibrofatty infiltration and conduction disturbances of myocardium. This process usually affects the ventricles, but recent studies showed also atrial involvement, which predisposes to atrial tachyarrhythmias (ATA). Catheter ablation (CA) efficacy for ATA in these patients (pts) is currently unknown
Objective: To investigate CA long-term outcomes for ATA in pts with AC
Methods: We retrospectively included pts with AC undergoing CA for ATA (atrial fibrillation (AF), atrial tachycardia (AT), and cavo-tricuspid isthmus dependent flutter (CTI-FL)) from 8 large registries in North America, Europe, and China. Baseline, procedural, and long-term outcome data were collected
Results: A total of 32 pts with AC (84% male, 91% definite diagnosis, median CHA2DS2-VASc 1 [1-2] and EHRA scores 2 [2-3]) were included. Mean age at first CA of ATA was 47.8 ± 15.4 y. At baseline, 63% of pts were on oral anticoagulants (OAC) (n = 9 warfarin; n = 11 NOAC). Left atrial (LA) CA including pulmonary vein isolation for AF/AT was performed in 25 (78%) pts and CA for CTI-FL was performed in 7 (22%). Sinus rhythm was obtained peri-procedurally in all pts. After a single procedure, over a follow up time of 36 [16.5 - 70] months 11 (34%) pts experienced an ATA recurrence (LA group: n = 6 AF recurrences, n = 3 AT recurrences; CTI-FL group: n = 1 CTI-FL recurrence; n = 1 new AF) and 66% pts were kept on OAC
Conclusion: AC pts receiving CA for ATA are mostly males and younger than the general population receiving CA for these arrhythmias. CA is safe and effective in pts with AC; surprisingly, long-term outcomes are comparable to those reported in trials in the general population.